What we do Ajanta Pharma Limited is a specialty pharmaceutical company focused on branded generics in India, Asia, and Africa, plus generics in the USA and institutional sales globally. |
Founded in 1,973 |
Market share Among the top pharmaceutical companies in branded generics in emerging markets, with leadership in key therapy areas. |
Problem solved Providing affordable, quality specialty medicines for chronic and infectious diseases across emerging and developed markets. |
Top clients or who we serve Pharmaceutical distributors, hospitals, government institutions, and patients across India, USA, Africa, and Asia; B2B and B2C focus. |
Key management Yogesh M. Agrawal (Managing Director), Rajesh M. Agrawal (Joint Managing Director) |
Our journey and innovations Founded in 1973, pioneered first-to-market specialty generics, expanded manufacturing with USFDA approvals, and steadily grew global footprint including US market entry in 2013. |
Where we operate India, over 30 emerging markets in Africa, CIS, Middle East, Southeast Asia, and the USA. |
Top products or what we offer Branded generics in cardiology, dermatology, ophthalmology, anti-infectives; generics for USA; anti-malarials under WHO programs in Africa. |
Top brands Pinkoo Gripe Water (iconic OTC), Montelukast formulations (first to market in USA), multiple specialty branded generics with leadership in cardiology and dermatology. |
Raw materials needed Active Pharmaceutical Ingredients (APIs), excipients, packaging materials sourced for formulation manufacturing. |
Raw materials supplier Suppliers include various domestic and international chemical and pharmaceutical raw material providers. |
Recurring vs cyclical contribution Majority revenue is recurring from ongoing branded generics sales, supported by stable institutional contracts. |
Our industry position Top 10 pharma company in Franco Africa, leading branded generics player in India and emerging markets, with increasing US market presence. |
Financial highlights FY 2025 consolidated revenue Rs 4648 crore, net profit Rs 920 crore, 10% revenue and 11% profit growth year-over-year. |
Geographical revenue split 68% exports to emerging markets and USA; India accounts for about 31% of revenue; institutional sales from Africa about 3%. |
Order book Not specifically disclosed, stable orders from branded generics and institutional contracts support growth. |
Whats driving growth First-to-market product launches, chronic therapy focus, geographic expansion, increased approvals in the USA, and robust R&D pipeline. |
Our future plans Capex focused on expanding manufacturing in Guwahati, Pithampur, Dahej and R&D facilities with ongoing product launches planned. |
Our green promise Committed to environmental sustainability through green initiatives and reducing paper usage, detailed ESG efforts reported separately. |
Our people and values Workforce of approximately 9,628 employees; emphasis on diversity, safety, and inclusive growth culture. |
Key challenges ahead Geopolitical tensions, global supply chain disruptions, regulatory scrutiny, and rising input costs remain risks with mitigation strategies in place. |
Interesting facts First generic company globally with WHO prequalification for anti-malarial drug; continuous product innovation since 1973. |
Risks and strategy Risks include regulatory compliance and market volatility; strategic focus on quality, compliance, and geographic diversification. |
